FDA grants orphan status to Clinuvel’s afamelanotide


NEW YORK The Food and Drug Administration has granted orphan drug status to Australia-based Clinuvel Pharmaceuticals’ drug for erythropoietic porphyries, afamelanotide.

The disease, which affects fair-skinned people, causes light sensitivity, severe pain, swelling and scarring. People with the disease must often stay indoors.

The FDA grants orphan status for drugs to treat rare illnesses.

This ad will auto-close in 10 seconds